Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Somatostatin Analogs Global Market Report 2025
Download Free Sample Buy Now
Global Somatostatin Analogs Market Report 2025

Report Price : $4490.00

Pages :

Format : PDF

Published : December 2025

Delivery Time : 2-3 Business Days

Purchase This Report Download Sample PDF
Purchase This Report

Somatostatin Analogs Global Market Report 2025

By Type (Octreotide, Lanreotide, Pasireotide), By Treatment (Acromegaly, Cushing’s Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Other Treatments), By End User (Hospital, Pharmaceutical Companies) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Somatostatin Analogs Market Overview

• Somatostatin Analogs market size has reached to $6.73 billion in 2024

• Expected to grow to $9.44 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%

• Growth Driver: Surge In Incidence Propels Growth In The Somatostatin Analogs Market

• Market Trend: Enhancing Precision Medicine With Advanced Somatostatin Analogs

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Somatostatin Analogs Market?

A somatostatin analog is a synthetic version of somatostatin that slows the production of hormones, such as serotonin and the growth hormone. It is used to reduce carcinoid syndrome symptoms, including diarrhea and skin flushing.

The main types of somatostatin analogs are octreotide, lanreotide, and pasireotide. Octreotide refers to a medication that blocks growth hormones like the naturally occurring somatostatin, which is used to treat certain forms of tumor-related diarrhea and flushing. These are used in acromegaly, Cushing’s syndrome, neuroendocrine tumors, carcinoid syndrome, and others, used by end users including hospitals and pharmaceutical companies.

Somatostatin Analogs Market Size and growth rate 2025 to 2029: Graph

What Is The Somatostatin Analogs Market Size 2025 And Growth Rate?

The somatostatin analogs market size has grown strongly in recent years. It will grow from$6.73 billion in 2024 to $7.16 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increased net incidence, advancements in oncology research, clinical efficacy in symptom management, expansion of indications, patient preference for long-acting formulations

What Is The Somatostatin Analogs Market Growth Forecast?

The somatostatin analogs market size is expected to see strong growth in the next few years. It will grow to $9.44 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to continued rise in net incidence, research focus on rare diseases, development of combination therapies, advancements in personalized medicine, global health initiatives in cancer care. Major trends in the forecast period include global aging population, healthcare infrastructure development in emerging markets, strategic collaborations and partnerships, pricing pressures and reimbursement challenges, technological integration in healthcare.

The forecast of 7.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. adoption of advanced neuroendocrine tumor management by inflating prices of somatostatin analog therapies developed in France and Denmark, resulting in delayed symptom control and higher specialty pharmacy expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Somatostatin Analogs Market Segmented?

1) By Type: Octreotide, Lanreotide, Pasireotide

2) By Treatment: Acromegaly, Cushing’s Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Other Treatments

3) By End User: Hospital, Pharmaceutical Companies

Subsegments:

1) By Octreotide: Long-Acting Release (LAR) Formulations, Short-Acting Formulations

2) By Lanreotide: Depot Formulations, Injectable Formulations

3) By Pasireotide: Long-Acting Injectable Formulations, Subcutaneous Formulations

What Is Driving The Somatostatin Analogs Market? Surge In Incidence Propels Growth In The Somatostatin Analogs Market

The rise in the incidence of neuroendocrine tumors is expected to propel the growth of the somatostatin analogs market going forward. Neuroendocrine tumors refer to malignancies that start in specialized neuroendocrine cells. Analogs of somatostatin prevent the body from producing too many hormones. They decrease a neuroendocrine tumor's growth and reduce carcinoid disease symptoms. For instance, according to Cancer Australia, an Australia-based national government agency, in 2022, around 5,437 new cases of neuroendocrine tumors were diagnosed in Australia, and it was estimated that a person has a 1 in 55 risks of being diagnosed with neuroendocrine tumors by the age of 85. Therefore, the rise in the incidence of neuroendocrine tumors is driving the growth of the somatostatin analogs industry.

What Is Driving The Somatostatin Analogs Market? Growing Aging Population Boost Somatostatin Analogs Market

The growing aging population market is expected to propel the growth of the somatostatin analogs market going forward. The aging population refers to a demographic shift characterized by a higher proportion or an increasing number of individuals in a society who are aged 65 years and older. The rise in the aging demographic correlates with a higher incidence of diseases that warrant the use of Somatostatin Analogs, driving the demand for these pharmaceuticals. For instance, in 2022, visual capitalist, a Canada based company creates and curates visual content focused on latest trends, there were 771 million people aged 65+ years globally, accounting for almost 10% of the world’s population. Therefore, the growing aging population is driving the growth of the somatostatin analogs industry.

Who Are The Major Players In The Global Somatostatin Analogs Market?

Major companies operating in the somatostatin analogs market include Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Midatech Pharma plc, Crinetics Pharmaceuticals Inc., Peptron Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Bayer Aktiengesellschaft, Cadila Healthcare Limited, Amneal Pharmaceuticals Inc., Recordati S.p.A., Amryt Pharma plc, Ipsen Pharma SA, Fresenius Kabi AG, Chiasma Inc., Merck KGaA, Sanofi S.A., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Viatris Inc., AstraZeneca plc, Johnson & Johnson, Genentech Inc., OctreoPharm Sciences GmbH

What Are The Key Trends Of The Global Somatostatin Analogs Market? Enhancing Precision Medicine With Advanced Somatostatin Analogs

Major companies operating in the somatostatin analogs market are focused on developing advanced products, such as targeted radiopharmaceuticals, to enhance the precision and effectiveness of cancer treatments, specifically for patients with somatostatin receptor-positive tumors. Targeted radiopharmaceuticals are specialized drugs that combine radiation-emitting isotopes with molecules designed to bind specifically to cancer cells, allowing for precise delivery of therapeutic radiation to tumor sites while minimizing exposure to surrounding healthy tissues. For instance, in January 2024, Lantheus, a US-based radiopharmaceutical-focused company, launched Lutetium Lu 177 Dotatate. Lutetium Lu-177 Dotatate is a radiolabeled somatostatin analog used in peptide receptor radionuclide therapy (PRRT) for treating advanced somatostatin receptor-positive neuroendocrine tumors. Clinical studies have demonstrated that it significantly improves progression-free survival and response rates compared to traditional somatostatin analogs like octreotide, making it a vital option for patients whose disease has progressed despite prior treatments. Its targeted approach allows for effective tumor control while minimizing systemic exposure, enhancing the overall therapeutic profile in managing neuroendocrine malignancies.

What Are The Key Trends Of The Global Somatostatin Analogs Market? Enhancing Patient Compliance With Novel Oral Somatostatin Agonists

Major companies operating in the somatostatin analogs market are focused on developing advanced products, such as oral selective agonists, to improve patient compliance and enhance the treatment of conditions associated with excess growth hormone, such as acromegaly. Oral selective agonists are compounds designed to selectively activate specific receptors in the body when administered orally, leading to targeted biological responses while minimizing effects on other receptor types. For instance, in September 2024, Crinetics Pharmaceuticals Inc., a US-based pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, submitted a new drug application for paltusotine for the treatment of acromegaly. Paltusotine is an oral, nonpeptide small-molecule agonist specifically targeting somatostatin receptor type 2 (SST2), developed for the treatment of acromegaly. This innovative drug offers a once-daily dosing regimen, enhancing patient compliance compared to traditional injectable somatostatin analogs like octreotide and lanreotide. Clinical studies have shown that paltusotine effectively lowers insulin-like growth factor I (IGF-I) levels, providing a promising alternative for patients requiring long-term management of hormone hypersecretion.

Need data on a specific region in this market?
Request Regional Data

Somatostatin Analogs Market Merger And Acquisition: Sun Pharmaceutical Collaborates With Philogen

In October 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company collaborated with Philogen S.p.A. to enhance its portfolio, expand access to innovative cancer treatments. Through this collaboration, Sun Pharmaceutical aims to enhance its portfolio, expand access to innovative cancer treatments, and commercialize the under-development skin cancer drug Nidlegy in Europe, Australia, and New Zealand. Philogen S.p.A. is an Italy-based biotechnology company focused on developing targeted therapeutics for oncology.

Regional Analysis For The Global Somatostatin Analogs Market

North America was the largest region in the global somatostatin analogs treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Somatostatin Analogs Market?

The somatostatin analogs market consists of sales of sandostatin, sandostatin lar, olatuton, somatuline LA, and somatuline autogel. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Somatostatin Analogs Industry?

The somatostatin analogs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the somatostatin analogs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Somatostatin Analogs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $7.16 billion
Revenue Forecast In 2034 $9.44 billion
Growth Rate CAGR of 7.2% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Type: Octreotide, Lanreotide, Pasireotide
2) By Treatment: Acromegaly, Cushing’s Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Other Treatments
3) By End User: Hospital, Pharmaceutical Companies Subsegments: 1) By Octreotide: Long-Acting Release (LAR) Formulations, Short-Acting Formulations
2) By Lanreotide: Depot Formulations, Injectable Formulations
3) By Pasireotide: Long-Acting Injectable Formulations, Subcutaneous Formulations
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Midatech Pharma plc, Crinetics Pharmaceuticals Inc., Peptron Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Bayer Aktiengesellschaft, Cadila Healthcare Limited, Amneal Pharmaceuticals Inc., Recordati S.p.A., Amryt Pharma plc, Ipsen Pharma SA, Fresenius Kabi AG, Chiasma Inc., Merck KGaA, Sanofi S.A., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Viatris Inc., AstraZeneca plc, Johnson & Johnson, Genentech Inc., OctreoPharm Sciences GmbH
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Somatostatin Analogs Market Characteristics

3. Somatostatin Analogs Market Trends And Strategies

4. Somatostatin Analogs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Somatostatin Analogs Growth Analysis And Strategic Analysis Framework

5.1. Global Somatostatin Analogs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Somatostatin Analogs Market Growth Rate Analysis

5.4. Global Somatostatin Analogs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Somatostatin Analogs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Somatostatin Analogs Total Addressable Market (TAM)

6. Somatostatin Analogs Market Segmentation

6.1. Global Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Octreotide

Lanreotide

Pasireotide

6.2. Global Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Acromegaly

Cushing’s Syndrome

Neuroendocrine Tumors

Carcinoid Syndrome

Other Treatments

6.3. Global Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital

Pharmaceutical Companies

6.4. Global Somatostatin Analogs Market, Sub-Segmentation Of Octreotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Long-Acting Release (LAR) Formulations

Short-Acting Formulations

6.5. Global Somatostatin Analogs Market, Sub-Segmentation Of Lanreotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Depot Formulations

Injectable Formulations

6.6. Global Somatostatin Analogs Market, Sub-Segmentation Of Pasireotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Long-Acting Injectable Formulations

Subcutaneous Formulations

7. Somatostatin Analogs Market Regional And Country Analysis

7.1. Global Somatostatin Analogs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Somatostatin Analogs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Somatostatin Analogs Market

8.1. Asia-Pacific Somatostatin Analogs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Somatostatin Analogs Market

9.1. China Somatostatin Analogs Market Overview

9.2. China Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Somatostatin Analogs Market

10.1. India Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Somatostatin Analogs Market

11.1. Japan Somatostatin Analogs Market Overview

11.2. Japan Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Somatostatin Analogs Market

12.1. Australia Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Somatostatin Analogs Market

13.1. Indonesia Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Somatostatin Analogs Market

14.1. South Korea Somatostatin Analogs Market Overview

14.2. South Korea Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Somatostatin Analogs Market

15.1. Western Europe Somatostatin Analogs Market Overview

15.2. Western Europe Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Somatostatin Analogs Market

16.1. UK Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Somatostatin Analogs Market

17.1. Germany Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Somatostatin Analogs Market

18.1. France Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Somatostatin Analogs Market

19.1. Italy Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Somatostatin Analogs Market

20.1. Spain Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Somatostatin Analogs Market

21.1. Eastern Europe Somatostatin Analogs Market Overview

21.2. Eastern Europe Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Somatostatin Analogs Market

22.1. Russia Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Somatostatin Analogs Market

23.1. North America Somatostatin Analogs Market Overview

23.2. North America Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Somatostatin Analogs Market

24.1. USA Somatostatin Analogs Market Overview

24.2. USA Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Somatostatin Analogs Market

25.1. Canada Somatostatin Analogs Market Overview

25.2. Canada Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Somatostatin Analogs Market

26.1. South America Somatostatin Analogs Market Overview

26.2. South America Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Somatostatin Analogs Market

27.1. Brazil Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Somatostatin Analogs Market

28.1. Middle East Somatostatin Analogs Market Overview

28.2. Middle East Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Somatostatin Analogs Market

29.1. Africa Somatostatin Analogs Market Overview

29.2. Africa Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Somatostatin Analogs Market Competitive Landscape And Company Profiles

30.1. Somatostatin Analogs Market Competitive Landscape

30.2. Somatostatin Analogs Market Company Profiles

30.2.1. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Sun Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Midatech Pharma plc Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Crinetics Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Somatostatin Analogs Market Other Major And Innovative Companies

31.1. Peptron Inc.

31.2. Teva Pharmaceutical Industries Ltd.

31.3. Camurus AB

31.4. Bayer Aktiengesellschaft

31.5. Cadila Healthcare Limited

31.6. Amneal Pharmaceuticals Inc.

31.7. Recordati S.p.A.

31.8. Amryt Pharma plc

31.9. Ipsen Pharma SA

31.10. Fresenius Kabi AG

31.11. Chiasma Inc.

31.12. Merck KGaA

31.13. Sanofi S.A.

31.14. Sandoz International GmbH

31.15. Takeda Pharmaceutical Company Limited

32. Global Somatostatin Analogs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Somatostatin Analogs Market

34. Recent Developments In The Somatostatin Analogs Market

35. Somatostatin Analogs Market High Potential Countries, Segments and Strategies

35.1 Somatostatin Analogs Market In 2029 - Countries Offering Most New Opportunities

35.2 Somatostatin Analogs Market In 2029 - Segments Offering Most New Opportunities

35.3 Somatostatin Analogs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Somatostatin Analogs Market, Sub-Segmentation Of Octreotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Somatostatin Analogs Market, Sub-Segmentation Of Lanreotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Somatostatin Analogs Market, Sub-Segmentation Of Pasireotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Somatostatin Analogs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Somatostatin Analogs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Novartis International AG Financial Performance
  • Table 78: Pfizer Inc. Financial Performance
  • Table 79: Sun Pharmaceutical Industries Limited Financial Performance
  • Table 80: Midatech Pharma plc Financial Performance
  • Table 81: Crinetics Pharmaceuticals Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Somatostatin Analogs Market, Sub-Segmentation Of Octreotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Somatostatin Analogs Market, Sub-Segmentation Of Lanreotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Somatostatin Analogs Market, Sub-Segmentation Of Pasireotide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Somatostatin Analogs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Somatostatin Analogs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Somatostatin Analogs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Somatostatin Analogs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Somatostatin Analogs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Novartis International AG Financial Performance
  • Figure 78: Pfizer Inc. Financial Performance
  • Figure 79: Sun Pharmaceutical Industries Limited Financial Performance
  • Figure 80: Midatech Pharma plc Financial Performance
  • Figure 81: Crinetics Pharmaceuticals Inc. Financial Performance

Intestinal Fistula Treatment Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Read More About Intestinal Fistula Treatment Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Next-Gen Invasive Aspergillosis Therapeutics : Market Forecast, Transformation, and Long-Term Trajectories

Read More About Next-Gen Invasive Aspergillosis Therapeutics : Market Forecast, Transformation, and Long-Term Trajectories

Iron Deficiency Anemia Growth Trajectory: Key Forecasts and Strategic Insights

Read More About Iron Deficiency Anemia Growth Trajectory: Key Forecasts and Strategic Insights

Lewy Body Dementia Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

Read More About Lewy Body Dementia Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

Read More About A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

Read More About A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Read More About A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Read More About A forward-looking 2025 report detailing projections, service trends and operational models in the medical accompaniment service market.

Somatostatin Analogs Global Market Report 2025 – By Type (Octreotide, Lanreotide, Pasireotide), By Treatment (Acromegaly, Cushing’s Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Other Treatments), By End User (Hos...

View Report

Sorbitol Global Market Report 2025 – By Product (Liquid, Crystal), By Application (Oral Care, Vitamin C, Diabetic And Dietetic Food And Beverage, Surfactant, Other Applications), By End User (Personal Care, Chemical, Foo...

View Report

Aspirin Global Market Report 2025 – By Product (Prescription, OTC), By Route Of Administration (Oral, Rectal, Parenteral ), By Dosage Form (Tablets, Capsules, Injections, Suppositories ), By Application (Cardiovascular D...

View Report

Sorbates Global Market Report 2025 – By Type (Sorbic Acid, Potassium Sorbate, Other Types), By Application (Food, Oils And Fats, Bakery And Confectionery, Dairy And Frozen Products, Snacks, Meat, Poultry, And Seafood, Be...

View Report

Peptide Therapeutics Global Market Report 2025 – By Type (Generic, Branded), By Route of Administration (Parenteral, Mucosal, Oral, Transdermal), By Application (Cancer, Cardiovascular Diseases, Central Nervous Systems, ...

View Report

Inotropic Agents Global Market Report 2025 – By Type (Positive Inotropic Drugs, Negative Inotropic Drugs, Other Types), By Route Of Administration (Oral, Parenteral, Other Routes Of Administration ), By Indication (Heart...

View Report

Ascorbic Acid Global Market Report 2025 – By Type (Calcium Ascorbate, Sodium Ascorbate, Magnesium Ascorbate, Potassium Ascorbate, D-Isoascorbic Ascorbate), By Grade (Pharmaceuticals Grade, Food Grade, Other Grades), By F...

View Report

Allogeneic Cell Therapy Global Market Report 2025 – By Type (Stem Cell Therapies, Non-Stem Cell Therapies ), By Therapeutic Area (Hematological Disorders, Dermatological Disorders, Other Therapeutic Area ), By End User (...

View Report

Frequently Asked Questions

A somatostatin analog is a synthetic version of somatostatin that slows the production of hormones, such as serotonin and the growth hormone. It is used to reduce carcinoid syndrome symptoms, including diarrhea and skin flushing. For further insights on this market, request a sample here

The market major growth driver - Surge In Incidence Propels Growth In The Somatostatin Analogs Market. For further insights on this market, request a sample here

The somatostatin analogs market size has grown strongly in recent years. It will grow from $6.73 billion in 2024 to $7.16 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increased net incidence, advancements in oncology research, clinical efficacy in symptom management, expansion of indications, patient preference for long-acting formulations. The somatostatin analogs market size is expected to see strong growth in the next few years. It will grow to " $9.44 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to continued rise in net incidence, research focus on rare diseases, development of combination therapies, advancements in personalized medicine, global health initiatives in cancer care. Major trends in the forecast period include global aging population, healthcare infrastructure development in emerging markets, strategic collaborations and partnerships, pricing pressures and reimbursement challenges, technological integration in healthcare. For further insights on this market, request a sample here

The somatostatin analogsmarket covered in this report is segmented –
1) By Type: Octreotide; Lanreotide; Pasireotide
2) By Treatment: Acromegaly; Cushing’s Syndrome; Neuroendocrine Tumors; Carcinoid Syndrome; Other Treatments
3) By End User: Hospital; Pharmaceutical Companies Subsegments:
1) By Octreotide: Long-Acting Release (LAR) Formulations; Short-Acting Formulations
2) By Lanreotide: Depot Formulations; Injectable Formulations
3) By Pasireotide: Long-Acting Injectable Formulations; Subcutaneous Formulations For further insights on this market, request a sample here

North America was the largest region in the global somatostatin analogs treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the somatostatin analogs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the somatostatin analogs market include Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Midatech Pharma plc, Crinetics Pharmaceuticals Inc., Peptron Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Bayer Aktiengesellschaft, Cadila Healthcare Limited, Amneal Pharmaceuticals Inc., Recordati S.p.A., Amryt Pharma plc, Ipsen Pharma SA, Fresenius Kabi AG, Chiasma Inc., Merck KGaA, Sanofi S.A., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Viatris Inc., AstraZeneca plc, Johnson & Johnson, Genentech Inc., OctreoPharm Sciences GmbH . For further insights on this market, request a sample here.

Major trends in this market include Enhancing Precision Medicine With Advanced Somatostatin Analogs. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Somatostatin Analogs Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon